SUVEN PHARMACEUTICALS SHARE PRICE
Emcure Pharmaceuticals IPO booked nearly 68 times so far on Day 3. Check GMP and other details
Emcure Pharmaceuticals IPO sees strong demand with oversubscription. Anchor investors include top names. Company engaged in global pharmaceutical products. Revenue growth and plans for debt payment outlined. Book-running lead managers identified.
Emcure Pharmaceuticals IPO fully subscribed on Day 1. Check GMP and other details
Emcure Pharmaceuticals' IPO attracts high demand from investors, with a price range of Rs 960-1008 per share. Analysts foresee business improvements and revenue growth potential in the global pharmaceutical market, supporting the company's expansion strategies.
Emcure Pharmaceuticals IPO booked nearly 5x so far on Day 2. Check GMP and other details
Emcure Pharmaceuticals' IPO has been oversubscribed nearly three times as of Thursday, the second day of bidding. The bidding concludes on July 5. The categories reserved for NII and retail investors were subscribed the most at 13 times and 3.43 times, respectively.
Share market update: Most active stocks of the day in terms of traded value
The NSE Nifty index closed 15.66 points up at 24302.15
Namita Thapar's Emcure Pharmaceuticals IPO opens on Wednesday. What GMP signals ahead of subscription
Emcure Pharmaceuticals' IPO opens for subscription on July 3rd with shares trading at a Rs 265 premium in the unlisted market. The IPO includes fresh equity shares worth Rs 800 crore and an Offer For Sale (OFS) of 1.14 crore shares. Priced at Rs 960-1,008 per share, investors can bid for 14 shares per lot. The company targets to raise Rs 1,952 crore at the upper price range.
Kotak Equities initiates coverage on JB Chemicals with a target price of Rs 2,025
“Having primarily grown organically until FY2022 and later on aided by benefits from acquired brands, JB has handsomely outperformed the IPM in the past decade by ~600 bps and currently ranks 22 in the IPM,” said Alankar Garude, Analyst at Kotak Equities.
- Go To Page 1
Emcure Pharmaceuticals IPO: 10 things to know before subscribing to the issue
Emcure Pharmaceuticals IPO is scheduled to open for subscription on July 3 and will close on July 5. The company aims to raise approximately Rs 1,952 crore through the public offer. Market analysts indicate that the current GMP of the pharma company stands at Rs 260 in the unlisted market.
Share market update: Most active stocks on D-Street today in terms of volume
The NSE Nifty index was trading 77.16 points up at 24087.75
Technical Breakout Stocks: How to trade UltraTech Cement, Suven Pharma and Titagarh Rail Systems on Friday
The Indian market closed in the green for the fourth day in a row on Thursday to hit fresh record highs. The S&P BSE Sensex climbed above 79,000 for the first time to hit a record high of 79,396 while the Nifty50 rose above 24,000 mark to hit a record high of 24,087.
Excited about gain in market share in US, says Biocon chief Kiran Mazumdar Shaw
Biocon Executive Chairperson Kiran Mazumdar Shaw say we've seen significant market share growth for our biosimilars in the US, exceeding our 20% global insulin market target sooner than expected. Demand has surged, especially for insulins, creating substantial opportunities.
Fosun to pare stake in Gland Pharma
Shanghai-based Fosun Pharmaceutical Group, the promoter of Gland Pharma, plans to sell up to a 5% stake in the company through a block deal to raise ₹1,435 crore ($172 million). This follows a successful IPO in November 2020 and is managed by UBS, as per a BSE filing. The offer price of ₹1,750 per share represents a 4.
Dr Reddy's signs in-licensing pact with Ingenus Pharmaceuticals for cancer treatment injection
Dr Reddy's Laboratories Ltd has signed a licensing agreement with US-based Ingenus Pharmaceuticals to commercialize Cyclophosphamide injection for cancer treatment. Dr Reddy's USA will commercialize the injection in the US market, paying Ingenus 50% of the calculated profit share.
GSM Foils shares list at IPO price on NSE SME platform
GSM Foils Share Price: GSM Foils lists on NSE SME at Rs 32 per share, with healthy IPO response of 250 times subscription. The company manufactures Blister Foils and Aluminium Pharma Foils for pharmaceutical packaging, capitalizing on India's robust pharmaceutical industry.
Stocks with tailwinds called advantage India: 5 largecap stocks from 3 different sectors with an upside potential of upto 36 %
In terms of valuations and sentiment we are not far from the place where we were in the last quarter of 2023 or early part of this year. When it was not possible to find stocks which can be called as “fairly valued” forget “undervalued”, and the sentiment was very bullish. The only difference between then and now is that we have election results which are coming up. Surely a confirmation on 4th June that continuity in the policy making is a big factor. But there is another thing which long term investors need to look at before investing. Whether the company or the sector has an advantage due to India as a country. A well known example, which has been present for decades is that of the IT industry. India as a country is a factory of software engineers, and that is our strength. So when investing for the long term, look at sectors where we have some strong tailwinds due to our human capital.
GSM Foils IPO opens today: Check issue size, price band, GMP & other details
GSM Foils IPO opens today to raise Rs 11 crore, listing on NSE SME platform. Shreni Shares manages the public offer for manufacturing Blister Foils and Aluminium Pharma Foils, with positive analyst projections.
Sun Pharma shares tumble 5% but brokerages raise target up to Rs 1,785. Should you buy, sell or hold?
In Thursday's trading session on the BSE, shares of Sun Pharmaceutical Industries declined by 5%, reaching the day's low of Rs 1,467. This drop occurred despite the company reporting a 34% year-on-year (YoY) increase in its Q4 profit to Rs 2,654.6 crore, with revenue rising by 10.1% YoY to Rs. 11,813 crore in Q4FY24.
Quest Labs stock debuts with 60% premium on NSE SME platform
Quest Laboratories made its debut on the NSE SME platform on Thursday, starting with a 60% premium. The stock opened at Rs 155, surpassing its issue price of Rs 97. Before its listing, the company's shares were trading at a premium of Rs 80 in the unlisted market.
Quest Laboratories IPO opens today: Check issue size, price band, GMP and other details
Quest Laboratories SME IPO opens today to raise Rs 43 crore through a fresh equity issue of 44.49 lakh shares at Rs 93-97 apiece on NSE SME platform. India's pharmaceutical industry, known for generic drugs and vaccines, ranks third globally with a 9.43% CAGR over nine years.
F&O stocks: Godrej Consumer Products, Cipla among 5 stocks with short buildup
In Tuesday's trading session, the following five stocks witnessed a build of fresh short positions. Let us first understand how this conclusion is reached that whether the stock has seen a buildup of fresh short position or not.
Lupin share price drops 5% post Q4 earnings
Lupin Share Price: Its revenue from operations in the same period jumped 12% YoY to Rs 4,961 crore as against Rs 4430 crore in the corresponding period of last year.
PE Advent International queues up for a stake in Apollo 24/7
Apollo 24/7 is part of Apollo HealthCo, a subsidiary of Apollo Hospitals. HealthCo also houses the pharmacy distribution business and a 25.5% interest in Apollo Pharmacy. It accounts for about 40% of Apollo Hospitals’ revenue.
Turnaround story: 40 smallcaps that lost over 30% in FY23, turn multibaggers in FY24
The FY24 has been a turnaround year for smallcap stocks, witnessing a significant rally with many stocks turning multibaggers. However, concerns over valuations raised by Sebi might moderate returns in FY25. While equity bulls partied hard in most of FY24, the Securities and Exchange Board India (Sebi) turned a party spoiler towards the end.
Merger effect! Suven Pharma shares jump 15% in 2 days
After the merger becomes effective, all shareholders of Cohance will be issued shares of Suven at the ratio of 11 shares of Suven for every 295 shares of Cohance, based on the swap ratio. The new shares of Suven will be traded on the NSE and BSE.
Suven Pharmaceuticals shares soar 13% on proposed merger with Cohance Lifesciences
Shares of Suven Pharmaceuticals surged 13% on the NSE after proposing a merger with Cohance Lifesciences to strengthen its CDMO industry position. After the merger, Advent entities will own 66.7%, and the transaction is expected to conclude in 12-15 months.
JSW Steel shares jump 4%, market cap crosses Rs 2 lakh crore mark. Here’s why
JSW Steel's shares rose 4.4% as it incorporated JSW Green Steel Ltd for steel product manufacturing. Its market cap surpassed Rs 2 lakh crore, making it the top Nifty gainer. The stock has delivered nearly 23% in the last 12 months, underperforming Nifty50.
Share market update: Most active stocks of the day in terms of total traded value
The NSE Nifty index was trading 196.86 points up at 22179.65
Load More
